TuHURA Biosciences Inc (NASDAQ:HURA), a Florida-based Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kineta Inc (OTC Pink:KANT), a Washington-based clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced on Tuesday that TuHURA stockholders approved all of the proposals set forth at the company's Special Meeting of Stockholders held on 23 June 2025.
The proposals included an increase of the company's authorised shares to 200 million shares, and a proposal to reincorporate the company in Delaware.
Additionally, Kineta stockholders approved the proposed merger with TuHURA at Kineta's Special Meeting of Stockholders held on 23 June 2025. The parties anticipate that the merger will close as soon as possible following the satisfaction or waiver of any remaining closing conditions.
Aptamer Group signs development and licensing deal with global life sciences partner
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
CivicaScript introduces low-cost multiple sclerosis treatment
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
BrightGene presents BGM0504 positive Phase 2 data for weight management and type 2 diabetes
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Amgen reports results of Phase 2 MariTide obesity study
Teva Pharmaceutical Industries reports positive final results from PEARL migraine study
Merck reports positive Phase 3 results for WINREVAIR in pulmonary arterial hypertension